For the Quarter Ending September 2025
North America
• In United States, the Diclofenac Potassium Price Index rose quarter-over-quarter in Q3 2025, driven by increasing production costs.
• Production costs increased due to a 2.6% PPI rise in August 2025 and 3.0% CPI in September 2025, impacting expenses.
• Demand for Diclofenac Potassium was supported by a 5.42% increase in retail sales in September 2025, boosting OTC purchases.
• A 4.3% unemployment rate in September 2025, with declining consumer confidence, suggested cautious spending affecting demand.
• North American natural gas demand growth in Q1-Q3 2025 contributed to higher energy feedstock costs for production.
• Industrial supplies and materials imports to the US significantly weakened in August 2025, impacting supply chain stability.
• US pharmaceutical preparations exports notably weakened in August 2025, influencing overall trade flows.
• US industrial production increased by 0.1% in September 2025, suggesting very slow growth in the manufacturing sector.
Why did the price of Diclofenac Potassium change in September 2025 in North America?
• Rising input costs, with PPI up 2.6% in August 2025, elevated Diclofenac Potassium production expenses.
• North American natural gas demand growth in Q1-Q3 2025 raised energy feedstock costs for manufacturing.
• Strong retail sales, up 5.42% in September 2025, supported demand for OTC Diclofenac Potassium.
APAC
• In China, the Diclofenac Potassium Price Index fell quarter-over-quarter in Q3 2025, driven by declining production costs and contracting manufacturing activity.
• Diclofenac Potassium production costs decreased in Q3 2025, influenced by a 2.3% decline in PPI in September 2025.
• Demand for Diclofenac Potassium was supported by a 3.0% rise in retail sales in September 2025, particularly for OTC applications.
• Overall chemical feedstock costs declined in Q3 2025, contributing to lower production expenses for Diclofenac Potassium.
• China's chemical production capacity expanded significantly in Q3 2025, leading to continued overcapacity and supply pressure.
• Pharmaceutical exports from China strengthened in Q3 2025, despite a contracting Manufacturing Index in September 2025.
• Consumer confidence at 89.6 and a stable 5.2% unemployment rate in September 2025 offered mixed demand signals.
• Industrial production grew by 6.5% in September 2025, supporting overall economic stability for Diclofenac Potassium demand.
Why did the price of Diclofenac Potassium change in September 2025 in APAC?
• Declining PPI of -2.3% in September 2025 reduced production costs for Diclofenac Potassium manufacturers.
• Contracting Manufacturing Index in September 2025 and chemical overcapacity created downward price pressure.
• Negative CPI of -0.3% in September 2025 indicated deflation, impacting consumer purchasing power for OTC products.
Europe
• In Germany, the Diclofenac Potassium Price Index fell quarter-over-quarter in Q3 2025, influenced by declining producer prices for chemicals.
• Production costs were positively impacted by a -1.7% PPI year-over-year in September 2025, indicating some cost reductions.
• Despite lower producer prices, the German chemical and pharma industry faced persistently high overall operational costs in Q3 2025.
• Diclofenac Potassium demand was constrained by cautious consumer spending and a stable 6.3% unemployment rate in September 2025.
• The Manufacturing Index contracted in Q3 2025, with industrial production declining 1.0% in September 2025, signaling weaker demand.
• Modest 0.2% year-over-year retail sales growth in September 2025 offered slight support for over-the-counter Diclofenac Potassium.
• Pharmaceutical production increased in July 2025, but the sector faced price and cost pressure in Germany during Q3 2025.
• Capacity utilization in the German chemical industry remained below profitability in Q3 2025, and exports fell significantly.
Why did the price of DICLOFENAC POTASSIUM change in September 2025 in Europe?
• Producer prices for chemicals and pharmaceuticals declined in Q3 2025, reducing manufacturing costs for Diclofenac Potassium.
• Weakening industrial production, down 1.0% in September 2025, and cautious consumer spending dampened overall Diclofenac Potassium demand.
• High operational costs, indicated by 2.4% CPI year-over-year in September 2025, partially offset production cost reductions.
